Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies

Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug Administration (FDA) has ...
Targeted Oncology

Novel ADC Earns FDA Fast Track in Head and Neck Cancer

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for ...
Medscape

FDA Puts Alopecia Treatment on Fast Track

The FDA has granted a “Fast Track” designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe alopecia areata, according to a press release from the manufacturer, Nektar ...
Cure Today

FDA Grants NX-5948 Fast Track Designation for R/R CLL, SLL

NX-5948 received FDA Fast Track designation for relapsed/refractory CLL and SLL after two prior therapies, including BTK and BCL2 inhibitors. Phase 1a/1b trial results show NX-5948 is safe, ...